AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Cloetta, you need to believe in a stable Nordic confectionery business that can steadily convert strong brands into cash, while carefully testing selective growth bets. The CandyKing flagship in New York looks more like a brand and insight laboratory than a near term profit driver, so it probably does not change the core short term catalysts, which still sit around upcoming earnings, margin resilience and how management uses its strengthened EUR 240 million debt facilities. What could shift is the narrative: a credible U.S. footprint may support brand equity and pricing power if the concept resonates, but it also adds execution risk and cost visibility questions that investors will watch closely, especially after the share price’s strong run this year.
However, one key risk could challenge the appeal of these expansion plans. Cloetta's shares have been on the rise but are still potentially undervalued by 33%. Find out what it's worth.Explore 7 other fair value estimates on Cloetta - why the stock might be worth 11% less than the current price!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com